Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 1 min

Exploring Material Basis and Q-Markers for Treatment of Alcoholic Liver Disease With Tetracera asiatica Tablets Based on In Vitro Components-In Vivo Transferring Components-Efficacy Targets

AI Summary
  • Six key compounds (kaempferol, eriodictyol, ellagic acid, catechin, quercetin, naringenin) form TA's core pharmacodynamic basis and candidate Q-markers.
  • UPLC-Q-Exactive MS characterised 170 constituents; 49 prototypes detected in mouse serum and liver, supporting in vitro to in vivo transfer.
  • TA ethanol extract reduced ethanol induced AST and ALT elevations; network, pathway and docking analyses implicate HIF-1, AGE-RAGE, JAK-STAT and targets SRC, BCL2, EGFR.
Summarise with AI (MRCPsych/FRANZCP)

Biomed Chromatogr. 2026 Dec;40(12):e70653. doi: 10.1002/bmc.70653.

ABSTRACT

This study aimed to clarify the therapeutic material basis of Tetracera asiatica (TA) against alcoholic liver disease (ALD) and predict its potential quality markers (Q-markers). UPLC-Q-Exactive Orbitrap HRMS, Progenesis QI 3.0 and reference compound database were adopted to characterize in vitro constituents, in vivo prototypes and postintragastric metabolites. Targets retrieved from multiple databases were used to construct a component-target-disease network, and molecular docking was performed to evaluate binding affinity. The ethanol extract of TA alleviated ethanol-induced increases in aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Among 170 characterized constituents, 49 were detected in mouse serum and liver, and 350 overlapping targets between TA and ALD were screened. Kaempferol, eriodictyol, ellagic acid, catechin, quercetin, and naringenin were key active constituents, functioning through HIF-1, AGE-RAGE, and JAK-STAT pathways and showing strong binding to SRC proto-oncogene, non-receptor tyrosine kinase (SRC), B-cell lymphoma-2 (BCL2), and epidermal growth factor receptor (EGFR). These six compounds constitute the core pharmacodynamic material basis of TA against ALD and are promising candidate Q-markers based on specificity, detectability, efficacy correlation, bioavailability, and TCM theory.

PMID:43012167 | DOI:10.1002/bmc.70653

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD